HCW Biologics said its proprietary multi-cytokine fusion protein reagent, HCW9206, offers a cost-effective way to generate higher-function CAR-T cells for immunotherapy.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
HCW Biologics' stock jumped 102.72% to $6.73 after the company revealed the successful development of second-generation T-cell engagers for solid tumors.
HCW Biologics Inc. (NASDAQ: HCWB) shares were up Monday after the company announced a breakthrough in developing second-generation pembrolizumab-based immunotherapies for solid tumors.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
